The IBD SmartSelect Composite Rating for Intuitive Surgical rose from 90 to 97 Tuesday.
The new rating shows the stock is outpacing 97% of all stocks when it comes to the most important stock-picking criteria. The market's biggest winners often have a 95 or higher score in the early stages of a new price run, so that's a good starting point when looking for the best stocks to buy and watch.
Intuitive Surgical is now out of buy range after breaking out from a flat base.
Lean How — And When — To Sell Stocks
The stock has a 94 EPS Rating, meaning its recent quarterly and longer-term annual earnings growth tops 94% of all stocks.
Its Accumulation/Distribution Rating of D shows moderate selling by institutional investors over the last 13 weeks. Look for the rating to improve to at least a C or better.
In Q4, the company reported 38% earnings-per-share growth. That marks three straight quarters of rising EPS performance. Sales growth increased 25%, up from 17% in the prior report. That marks three quarters of increasing revenue gains. The company's next quarterly report is expected on or around Apr. 22.
Intuitive Surgical earns the No. 1 rank among its peers in the Medical-Systems/Equipment industry group. iRadimed and Masimo are also among the group's highest-rated stocks.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
